NeftalyApp Courses Partner Invest Corporate Charity Divisions

Neftaly Hospital

Neftaly Email: sayprobiz@gmail.com Call/WhatsApp: + 27 84 313 7407

Tag: oncology.

Neftaly Email: sayprobiz@gmail.com Call/WhatsApp: + 27 84 313 7407

[Contact Neftaly] [About Neftaly][Services] [Recruit] [Agri] [Apply] [Login] [Courses] [Corporate Training] [Study] [School] [Sell Courses] [Career Guidance] [Training Material] [ListBusiness/NPO/Govt] [Shop] [Volunteer] [Internships] [Jobs] [Tenders] [Funding] [Learnerships] [Bursary] [Freelancers] [Sell] [Camps] [Events&Catering] [Research] [Laboratory] [Sponsor] [Machines] [Partner] [Advertise]  [Influencers] [Publish] [Write ] [Invest ] [Franchise] [Staff] [CharityNPO] [Donate] [Give] [Clinic/Hospital] [Competitions] [Travel] [Idea/Support] [Events] [Classified] [Groups] [Pages]

  • Neftaly Pediatric oncology supportive care advancements

    Neftaly Pediatric oncology supportive care advancements

    Neftaly does (supported by sources):

    • Cancer Survivor Support: Neftaly empowers cancer survivors through partnerships and offers services like grocery and transport help, counseling, and employment assistance. saypro.online
    • Clinical Trial Volunteer Support: Through its Southern Africa Youth Project, Neftaly facilitates clinical trial participation by providing logistical and emotional support to volunteers. southernafricayouth.org
    • Child Health Improvement: Neftaly runs programs focused on enhancing child health through nutritional guidance, immunization, preventive care, and exercise promotion. saypro.online
    • Retinal Degeneration Projects: In collaboration with research institutions, Neftaly assists in genetic testing, awareness campaigns, and patient support related to hereditary eye conditions. saypro.online
    • Youth-Friendly Health Advocacy: Neftaly supports youth access to healthcare, education, and psychosocial services, especially in communities like Diepsloot. diepslootyouth.org.za+1

    What Neftaly doesn’t (yet) do—based on current public information:

    • Provide pediatric oncology supportive care programs (i.e., specific services for children undergoing cancer treatment such as symptom management, palliative care, nutritional support, or survivorship planning).
    • Publish formal guidelines or clinical tools for cancer care in pediatrics.
    • Offer dedicated research or initiatives in pediatric supportive oncology.

    Broader Landscape: Pediatric Oncology Supportive Care

    Though Neftaly hasn’t been documented in pediatric oncology, the field is advancing globally. Notable developments include:

    • Clinical Practice Guidelines (CPGs): There’s been a growing movement to create pediatric-specific guidelines to standardize supportive care—making it evidence-based and consistent. These started emerging around 2011 (e.g., emetogenicity classification), with further expansion through entities like MASCC and the iPOG Network. MDPI
    • Patient-Reported Outcomes (PROs): Integrating PROs in care planning is increasingly viewed as essential to tailor support, manage symptoms, and enhance quality of life. MDPIASCOPubs
    • Holistic Care Models: Emphasis is growing on treating pediatric oncology patients as children first—by addressing nutrition, development, activity, growth, psychological health, and ensuring smooth survivorship transitions. MDPIPMC

    These initiatives underline global priorities: evidence-based supportive care, personalization, and child-centric approaches across the oncology journey.

    Bridging the Gap: Potential Directions for Neftaly

    If Neftaly were interested in expanding into pediatric oncology supportive care, there are several promising paths:

    1. Develop and Implement Local CPGs: Collaborate with pediatric oncology centers or professional bodies to create standardized supportive care protocols tailored to South African contexts.
    2. Integrate PROs into Practice: Launch initiatives to collect and utilize patient-reported outcomes from children and caregivers—informing service design and quality improvement.
    3. Support Holistic Needs: Extend programs for cancer survivors to younger patients by offering nutritional counseling, psychological support, pain management, school reintegration assistance, and family education.
    4. Strengthen Infrastructure & Training: Using models like the PrOFILE tool (that assesses and recommends enhancements for pediatric oncology facilities in South Africa), Neftaly could support capacity building and resource allocation. sahr.hst.org.za

    Summary Table: Neftaly vs. Pediatric Oncology Supportive Care

    DomainNeftaly Currently OffersPediatric Oncology Supportive Care Needs
    Cancer Survivor SupportYes (survivor assistance programs)Extend to pediatric cancer patients
    Clinical Trials SupportYes (logistics, volunteer program)Adapt for families of pediatric oncology trial participants
    Child Health ProgramsYes (nutrition, prevention, check-ups)Incorporate pediatric cancer‑specific support services
    Retinal Degeneration InitiativesYes (genetic testing, awareness, referrals)N/A
    Youth Healthcare AdvocacyYes (clinics, youth empowerment)Include pediatric oncology awareness and access initiatives
    CPGs / Evidence‑based ProtocolsNo public involvement in oncologyCreate or adopt pediatric oncology supportive care guidelines
    Patient‑Reported Outcomes (PROs)Not yet used in oncology or supportive programsIntegrate for symptom and quality-of-life tracking
    Clinical/Facility Capacity BuildingGeneral health supportSupport pediatric oncology infrastructure (e.g., via PrOFILE)

    Invitation to Explore Further

  • Neftaly Pediatric oncology clinical trial outcomes

    Neftaly Pediatric oncology clinical trial outcomes

  • Neftaly Oncology Treatment Availability

    Neftaly Oncology Treatment Availability

    Neftaly Oncology Treatment Availability

    Cancer is one of the leading causes of death globally, yet access to timely, affordable, and quality oncology treatment remains uneven across regions. At Neftaly, we are committed to improving oncology treatment availability by addressing gaps in infrastructure, workforce, and policy to ensure that no patient is left behind.

    The Global Challenge of Cancer Care

    Millions of people around the world face delays in diagnosis and limited access to life-saving treatments due to:

    • Insufficient Oncology Infrastructure: Many regions lack specialized cancer centers, radiotherapy machines, and diagnostic tools.
    • Shortage of Trained Specialists: There is a global shortage of oncologists, oncology nurses, and support staff.
    • High Cost of Treatment: Chemotherapy, radiation, immunotherapy, and surgery are often unaffordable or unavailable, especially in low-resource settings.
    • Urban-Rural Disparities: Rural and remote communities frequently have little to no access to cancer care services.
    • Limited Early Detection and Screening: Late-stage diagnoses are common where preventive services are underdeveloped.

    Neftaly’s Approach to Expanding Oncology Treatment Access

    At Neftaly, we work across sectors to improve oncology treatment availability through:

    • Facility Development: Supporting the establishment and upgrading of oncology units and cancer treatment centers.
    • Workforce Capacity Building: Training healthcare providers in cancer diagnosis, treatment, and palliative care.
    • Policy Advocacy: Working with governments to develop national cancer control strategies and ensure cancer care is included in universal health coverage.
    • Technology Integration: Promoting tele-oncology, AI diagnostics, and digital health solutions for remote consultations and care coordination.
    • Public Awareness & Screening: Increasing awareness and early detection through education campaigns and mobile outreach programs.

    Our Impact Areas

    • Chemotherapy and Radiation Access
    • Pediatric and Adult Oncology Programs
    • Cancer Surgery and Specialized Procedures
    • Supportive and Palliative Oncology Care
    • Patient Navigation and Survivorship Programs

    Why Partner with Neftaly?

    • Deep expertise in cancer care systems and infrastructure development
    • Global network of oncology experts and training programs
    • Commitment to equitable, patient-centered care
    • Proven track record of delivering results in resource-limited settings

    Bringing Hope through Expanded Oncology Access with Neftaly

    Cancer should not be a death sentence due to lack of access. Contact Neftaly to learn how we are helping communities build resilient, inclusive, and life-saving oncology care systems.

  • Neftaly Collaboration on Cancer Immuno-Oncology Trials

    Neftaly Collaboration on Cancer Immuno-Oncology Trials

  • Neftaly Advances in clinical oncology for hematologic malignancies

    Neftaly Advances in clinical oncology for hematologic malignancies

    Advances in Clinical Oncology for Hematologic Malignancies

    Introduction

    Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, represent a diverse group of blood cancers that have historically posed significant treatment challenges. However, rapid advancements in clinical oncology are transforming patient outcomes through precision medicine, novel therapeutics, and innovative diagnostic tools.

    At Neftaly, we highlight these breakthroughs that are reshaping the management of hematologic malignancies, offering new hope for patients and clinicians alike.

    Key Advances in Hematologic Oncology

    1. Precision and Targeted Therapies

    The advent of targeted therapies has revolutionized treatment by focusing on specific molecular abnormalities driving cancer progression. Examples include:

    • Tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), dramatically improving survival rates.
    • Monoclonal antibodies like rituximab targeting CD20 in non-Hodgkin lymphoma.
    • BCL-2 inhibitors (e.g., venetoclax) that promote apoptosis in certain leukemias.
      These therapies offer increased efficacy with reduced systemic toxicity compared to traditional chemotherapy.

    2. Immunotherapy Breakthroughs

    Harnessing the immune system to combat hematologic cancers has yielded remarkable success:

    • CAR-T cell therapy involves genetically modifying a patient’s T cells to recognize and attack malignant cells, particularly in relapsed or refractory B-cell malignancies.
    • Checkpoint inhibitors unleash immune responses by blocking proteins that inhibit T cell activity, showing promise in Hodgkin lymphoma and other blood cancers.

    3. Advances in Stem Cell Transplantation

    Improvements in allogeneic and autologous hematopoietic stem cell transplantation, including better conditioning regimens and graft-versus-host disease (GVHD) management, have enhanced long-term remission and survival. Reduced-intensity conditioning expands eligibility to older or comorbid patients.

    4. Enhanced Molecular Diagnostics and Minimal Residual Disease (MRD) Monitoring

    Cutting-edge molecular assays allow for precise disease classification, risk stratification, and treatment tailoring. MRD detection using next-generation sequencing (NGS) or flow cytometry guides therapeutic decisions and predicts relapse, enabling early intervention.

    5. Integration of Digital Health and Artificial Intelligence

    Digital tools and AI algorithms are optimizing diagnosis, prognostication, and treatment personalization. Predictive models improve patient monitoring, optimize clinical trial design, and support decision-making in complex cases.

    Challenges and Future Directions

    Despite these advances, challenges remain, including treatment resistance, accessibility issues, and managing long-term toxicities. Ongoing clinical trials continue to explore combination therapies, novel agents, and innovative delivery systems.

    The future of hematologic oncology lies in multi-disciplinary collaboration, integrating genomics, immunology, and digital health to provide truly personalized care.

    Conclusion

    The landscape of clinical oncology for hematologic malignancies is rapidly evolving, driven by scientific innovation and a deeper understanding of cancer biology. These advances are translating into improved survival rates, better quality of life, and renewed hope for patients worldwide.

    Neftaly is committed to supporting healthcare providers by delivering insights and tools that empower the adoption of cutting-edge therapies and optimize patient outcomes in hematologic oncology.

  • Neftaly Advances in clinical oncology for personalized radiotherapy

    Neftaly Advances in clinical oncology for personalized radiotherapy

    Advances in Clinical Oncology for Personalized Radiotherapy

    Introduction

    Radiotherapy has long been a cornerstone of cancer treatment, used in approximately 50% of all cancer patients. Today, the field is undergoing a transformative shift — moving from standardized protocols to personalized radiotherapy strategies that tailor treatment to the unique biological and clinical characteristics of each patient.

    At Neftaly, we explore how cutting-edge technologies, data analytics, and biological insights are driving precision in radiotherapy, enhancing outcomes while reducing toxicity.

    What is Personalized Radiotherapy?

    Personalized radiotherapy involves customizing treatment plans based on individual tumor biology, genetics, imaging data, and patient-specific factors. This approach ensures that radiation is delivered:

    • At the right dose
    • To the right target
    • With minimal impact on surrounding healthy tissue

    The goal is to maximize tumor control while preserving quality of life.

    Key Advances Fueling Personalized Radiotherapy

    1. Genomic and Molecular Profiling

    • Radiogenomics connects genetic markers with radiation response, allowing clinicians to predict radiosensitivity or resistance.
    • Biomarkers (e.g., TP53, ATM, EGFR mutations) guide decisions on dose escalation or de-escalation.
    • Molecular profiling enables stratification of patients for combined therapies (e.g., radiotherapy + immunotherapy).

    2. Functional and Molecular Imaging

    • PET, MRI, and functional CT are now used not just for staging, but to guide adaptive planning and monitor treatment response.
    • Radiomics extracts quantitative features from images to build predictive models, identifying aggressive tumor subregions for targeted boost dosing.

    3. Adaptive Radiotherapy (ART)

    • ART uses frequent imaging to adjust treatment plans in real time, accounting for changes in tumor size, shape, or position during the treatment course.
    • Enables more precise delivery and reduces unnecessary exposure to healthy tissue.

    4. Artificial Intelligence and Machine Learning

    • AI algorithms assist in treatment planning, contouring, and dose optimization based on historical and real-time data.
    • Machine learning models predict toxicity risks and help tailor follow-up care.

    5. Particle Therapy and Advanced Modalities

    • Proton therapy and carbon ion therapy offer highly conformal dose delivery with reduced exit dose, making them ideal for tumors near critical structures.
    • These modalities are especially beneficial in pediatric oncology and radioresistant tumors.

    6. Integration with Immunotherapy and Targeted Agents

    • Combining radiotherapy with checkpoint inhibitors or targeted therapies enhances immune response and radiosensitization.
    • Ongoing trials are exploring optimal combinations and sequences for various tumor types.

    Clinical Applications

    • Breast Cancer: Genomic assays guide decisions on radiotherapy omission or intensification.
    • Prostate Cancer: MRI-guided radiotherapy enables focal boosts to dominant intraprostatic lesions.
    • Head and Neck Cancer: Adaptive techniques reduce dose to salivary glands, preserving function.
    • Glioblastoma: Personalized dosing strategies are being investigated based on molecular signatures and tumor kinetics.

    Benefits of Personalized Radiotherapy

    ✅ Improved tumor control
    ✅ Reduced treatment-related toxicity
    ✅ Better patient-reported outcomes
    ✅ Optimized use of healthcare resources
    ✅ Enhanced integration with systemic therapies

    Challenges and Considerations

    • Data integration: Combining genomics, imaging, and clinical data requires robust infrastructure.
    • Access and cost: Advanced techniques like proton therapy remain limited in availability.
    • Workforce training: Radiation oncologists, physicists, and dosimetrists must be equipped to apply emerging tools.
    • Regulatory and reimbursement frameworks need to evolve to support innovation.

    Conclusion

    Personalized radiotherapy represents the future of clinical oncology — combining the power of technology, biology, and data to deliver safer, smarter, and more effective cancer treatment. As research evolves and tools become more accessible, tailored radiotherapy is poised to become the new standard of care.

    At Neftaly, we are committed to advancing oncology education, clinical practice, and technology adoption to empower professionals in delivering precision-driven, patient-centered care.

  • Neftaly Advances in clinical molecular oncology for early detection

    Neftaly Advances in clinical molecular oncology for early detection

  • Neftaly Ethical considerations in managing consent in pediatric oncology trials

    Neftaly Ethical considerations in managing consent in pediatric oncology trials

  • Neftaly AI for optimizing treatment protocols in oncology.

    Neftaly AI for optimizing treatment protocols in oncology.

    Neftaly AI: Optimizing Treatment Protocols in Oncology

    Oncology is one of the most complex and rapidly evolving fields of medicine, where personalized treatment can make the difference between life and death. Neftaly leverages advanced artificial intelligence to optimize cancer treatment protocols — helping oncologists deliver precision therapies tailored to each patient’s unique tumor biology, medical history, and response patterns.

    Precision Oncology Powered by AI

    Neftaly’s AI platform integrates vast amounts of clinical data, genomic information, imaging, and treatment outcomes to support oncologists in selecting and refining therapies that maximize efficacy while minimizing side effects.

    How Neftaly AI Enhances Oncology Treatment:

    • Data-Driven Treatment Personalization
      Neftaly analyzes genetic markers, tumor profiles, and patient health status to recommend targeted therapies and combination regimens optimized for individual cases.
    • Predictive Response Modeling
      Our AI predicts patient responses to various treatment options, helping clinicians anticipate effectiveness and adjust protocols proactively.
    • Adaptive Protocol Adjustments
      Neftaly continuously monitors patient progress and real-time data, enabling dynamic treatment modifications that respond to changing tumor behavior or patient tolerance.
    • Clinical Trial Matching
      The platform identifies suitable clinical trials for patients based on their unique profiles, expanding access to cutting-edge therapies.
    • Reduced Toxicity and Improved Quality of Life
      By optimizing treatment plans, Neftaly aims to minimize adverse effects, improving patient comfort and adherence.

    Supporting Oncologists with Actionable Insights

    Neftaly integrates seamlessly with oncology workflows and electronic health records (EHRs), providing clinicians with clear, evidence-based recommendations that enhance decision-making and patient care.

    Neftaly: Transforming Cancer Care Through AI-Driven Treatment Optimization

    With Neftaly AI, oncologists gain a powerful ally in the fight against cancer — accelerating precision medicine, improving outcomes, and advancing personalized care.

    Partner with Neftaly to harness AI’s potential and deliver the next generation of oncology treatment protocols.